<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">31980023</PMID>
      <DateCompleted>
        <Year>2021</Year>
        <Month>01</Month>
        <Day>12</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2021</Year>
        <Month>01</Month>
        <Day>12</Day>
      </DateRevised>
      <Article PubModel="Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1476-4598</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>19</Volume>
            <Issue>1</Issue>
            <PubDate>
              <Year>2020</Year>
              <Month>Jan</Month>
              <Day>24</Day>
            </PubDate>
          </JournalIssue>
          <Title>Molecular cancer</Title>
          <ISOAbbreviation>Mol Cancer</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Circulating tumor cells in cancer patients: developments and clinical applications for immunotherapy.</ArticleTitle>
        <Pagination>
          <StartPage>15</StartPage>
          <MedlinePgn>15</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="pii" ValidYN="Y">15</ELocationID>
        <ELocationID EIdType="doi" ValidYN="Y">10.1186/s12943-020-1141-9</ELocationID>
        <Abstract>
          <AbstractText>Cancer metastasis is the leading cause of cancer-related death. Circulating tumor cells (CTCs) are shed into the bloodstream from either primary or metastatic tumors during an intermediate stage of metastasis. In recent years, immunotherapy has also become an important focus of cancer research. Thus, to study the relationship between CTCs and immunotherapy is extremely necessary and valuable to improve the treatment of cancer. In this review, based on the advancements of CTC isolation technologies, we mainly discuss the clinical applications of CTCs in cancer immunotherapy and the related immune mechanisms of CTC formation. In order to fully understand CTC formation, sufficiently and completely understood molecular mechanism based on the different immune cells is critical. This understanding is a promising avenue for the development of effective immunotherapeutic strategies targeting CTCs.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Zhong</LastName>
            <ForeName>Xiaoming</ForeName>
            <Initials>X</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Pathology, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, Guangdong, China.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>School of Medicine, Sun Yat-sen University, Guangzhou, Guangdong, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Zhang</LastName>
            <ForeName>Hangtian</ForeName>
            <Initials>H</Initials>
            <AffiliationInfo>
              <Affiliation>School of Medicine, Sun Yat-sen University, Guangzhou, Guangdong, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Zhu</LastName>
            <ForeName>Ying</ForeName>
            <Initials>Y</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Radiology, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, Guangdong, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Liang</LastName>
            <ForeName>Yuqing</ForeName>
            <Initials>Y</Initials>
            <AffiliationInfo>
              <Affiliation>The Dietrich School of Arts and Sciences, University of Pittsburgh, Pittsburgh, Commonwealth of Pennsylvania, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Yuan</LastName>
            <ForeName>Zhuolin</ForeName>
            <Initials>Z</Initials>
            <AffiliationInfo>
              <Affiliation>School of Medicine, Sun Yat-sen University, Guangzhou, Guangdong, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Li</LastName>
            <ForeName>Jiachen</ForeName>
            <Initials>J</Initials>
            <AffiliationInfo>
              <Affiliation>School of Medicine, Sun Yat-sen University, Guangzhou, Guangdong, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Li</LastName>
            <ForeName>Jing</ForeName>
            <Initials>J</Initials>
            <AffiliationInfo>
              <Affiliation>School of Medicine, Sun Yat-sen University, Guangzhou, Guangdong, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Li</LastName>
            <ForeName>Xin</ForeName>
            <Initials>X</Initials>
            <AffiliationInfo>
              <Affiliation>School of Medicine, Sun Yat-sen University, Guangzhou, Guangdong, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Jia</LastName>
            <ForeName>Yifan</ForeName>
            <Initials>Y</Initials>
            <AffiliationInfo>
              <Affiliation>School of Medicine, Sun Yat-sen University, Guangzhou, Guangdong, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>He</LastName>
            <ForeName>Tian</ForeName>
            <Initials>T</Initials>
            <AffiliationInfo>
              <Affiliation>School of Medicine, Sun Yat-sen University, Guangzhou, Guangdong, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Zhu</LastName>
            <ForeName>Jiangyuan</ForeName>
            <Initials>J</Initials>
            <AffiliationInfo>
              <Affiliation>School of Medicine, Sun Yat-sen University, Guangzhou, Guangdong, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Sun</LastName>
            <ForeName>Yu</ForeName>
            <Initials>Y</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Pathology, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, Guangdong, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Jiang</LastName>
            <ForeName>Wengting</ForeName>
            <Initials>W</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Pathology, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, Guangdong, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Zhang</LastName>
            <ForeName>Hui</ForeName>
            <Initials>H</Initials>
            <AffiliationInfo>
              <Affiliation>Precision Medicine Institute, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, Guangdong, China. sysuzhanghui@163.com.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Wang</LastName>
            <ForeName>Cheng</ForeName>
            <Initials>C</Initials>
            <AffiliationInfo>
              <Affiliation>Division of Nephrology, Department of medicine, The Fifth Hospital of Sun Yat-sen University, Zhuhai, 519000, Guangdong, China. WT770716@163.com.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Ke</LastName>
            <ForeName>Zunfu</ForeName>
            <Initials>Z</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Pathology, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, Guangdong, China. kezunfu@mail.sysu.edu.cn.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Precision Medicine Institute, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, Guangdong, China. kezunfu@mail.sysu.edu.cn.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
          <PublicationType UI="D016454">Review</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2020</Year>
          <Month>01</Month>
          <Day>24</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>Mol Cancer</MedlineTA>
        <NlmUniqueID>101147698</NlmUniqueID>
        <ISSNLinking>1476-4598</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D014408">Biomarkers, Tumor</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D007155">Immunologic Factors</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D014408" MajorTopicYN="N">Biomarkers, Tumor</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D007155" MajorTopicYN="N">Immunologic Factors</DescriptorName>
          <QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D007167" MajorTopicYN="N">Immunotherapy</DescriptorName>
          <QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009369" MajorTopicYN="N">Neoplasms</DescriptorName>
          <QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName>
          <QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
          <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009360" MajorTopicYN="N">Neoplastic Cells, Circulating</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
          <QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
          <QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="Y">Circulating tumor cells (CTCs)</Keyword>
        <Keyword MajorTopicYN="Y">Immune mechanisms</Keyword>
        <Keyword MajorTopicYN="Y">Immunotherapy</Keyword>
        <Keyword MajorTopicYN="Y">Isolation technologies</Keyword>
        <Keyword MajorTopicYN="Y">Prognosis</Keyword>
      </KeywordList>
      <CoiStatement>All authors declare that they have no competing interests.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2019</Year>
          <Month>11</Month>
          <Day>3</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2020</Year>
          <Month>1</Month>
          <Day>16</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2020</Year>
          <Month>1</Month>
          <Day>26</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2020</Year>
          <Month>1</Month>
          <Day>26</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2021</Year>
          <Month>1</Month>
          <Day>13</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>epublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">31980023</ArticleId>
        <ArticleId IdType="pmc">PMC6982393</ArticleId>
        <ArticleId IdType="doi">10.1186/s12943-020-1141-9</ArticleId>
        <ArticleId IdType="pii">10.1186/s12943-020-1141-9</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Pitroda SP, Chmura SJ, Weichselbaum RR. Integration of radiotherapy and immunotherapy for treatment of oligometastases. Lancet Oncol. 2019;20(8):e434–e442. doi: 10.1016/S1470-2045(19)30157-3.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S1470-2045(19)30157-3</ArticleId>
            <ArticleId IdType="pubmed">31364595</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Luke JJ, Flaherty KT, Ribas A. Long GV4. Targeted agents and immunotherapies: optimizing outcomes in melanoma. Nat Rev Clin Oncol. 2017;14(8):463–482. doi: 10.1038/nrclinonc.2017.43.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nrclinonc.2017.43</ArticleId>
            <ArticleId IdType="pubmed">28374786</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Herbst RS, Morgensztern D, Boshoff C. The biology and management of non-small cell lung cancer. Nature. 2018;553(7689):446–454. doi: 10.1038/nature25183.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nature25183</ArticleId>
            <ArticleId IdType="pubmed">29364287</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Carlo MI, Voss MH, Motzer RJ. Checkpoint inhibitors and other novel immunotherapies for advanced renal cell carcinoma. Nat Rev Urol. 2016;13(7):420–431. doi: 10.1038/nrurol.2016.103.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nrurol.2016.103</ArticleId>
            <ArticleId IdType="pmc">PMC5532875</ArticleId>
            <ArticleId IdType="pubmed">27324121</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Schmidt C. The benefits of immunotherapy combinations. Nature. 2017;552(7685):S67–S69. doi: 10.1038/d41586-017-08702-7.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/d41586-017-08702-7</ArticleId>
            <ArticleId IdType="pubmed">29293245</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ye Q, Ling S, Zheng S, Xu X. Liquid biopsy in hepatocellular carcinoma: circulating tumor cells and circulating tumor DNA. Mol Cancer. 2019;18(1):114. doi: 10.1186/s12943-019-1043-x.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/s12943-019-1043-x</ArticleId>
            <ArticleId IdType="pmc">PMC6607541</ArticleId>
            <ArticleId IdType="pubmed">31269959</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Diaz LA, Jr, Bardelli A. Liquid biopsies: genotyping circulating tumor DNA. J Clin Oncol. 2014;32(6):579–586. doi: 10.1200/JCO.2012.45.2011.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1200/JCO.2012.45.2011</ArticleId>
            <ArticleId IdType="pmc">PMC4820760</ArticleId>
            <ArticleId IdType="pubmed">24449238</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Alix-Panabières C, Pantel K. Clinical applications of circulating tumor cells and circulating tumor DNA as liquid biopsy. Cancer Discov. 2016;6(5):479–491. doi: 10.1158/2159-8290.CD-15-1483.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/2159-8290.CD-15-1483</ArticleId>
            <ArticleId IdType="pubmed">26969689</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Watts G. Liquid biopsy: still early days for early detection. Lancet. 2018;391(10140):2593–2594. doi: 10.1016/S0140-6736(18)31476-4.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S0140-6736(18)31476-4</ArticleId>
            <ArticleId IdType="pubmed">30070213</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lin M, Liang SZ, Shi J, Niu LZ, Chen JB, Zhang MJ, et al.  Circulating tumor cell as a biomarker for evaluating allogenic NK cell immunotherapy on stage IV non-small cell lung cancer. Immunol Lett. 2017;191:10–15. doi: 10.1016/j.imlet.2017.09.004.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.imlet.2017.09.004</ArticleId>
            <ArticleId IdType="pubmed">28916277</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Qin Z, Chen J, Zeng J, Niu L, Xie S, Wang X, et al.  Effect of NK cell immunotherapy on immune function in patients with hepatic carcinoma: a preliminary clinical study. Cancer Biol Ther. 2017;18(5):323–330. doi: 10.1080/15384047.2017.1310346.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1080/15384047.2017.1310346</ArticleId>
            <ArticleId IdType="pmc">PMC5499755</ArticleId>
            <ArticleId IdType="pubmed">28353401</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yang Y, Qin Z, Du D, Wu Y, Qiu S, Mu F, et al.  Safety and short-term efficacy of irreversible electroporation and Allogenic natural killer cell immunotherapy combination in the treatment of patients with Unresectable primary liver Cancer. Cardiovasc Intervent Radiol. 2019;42(1):48–59. doi: 10.1007/s00270-018-2069-y.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s00270-018-2069-y</ArticleId>
            <ArticleId IdType="pmc">PMC6267679</ArticleId>
            <ArticleId IdType="pubmed">30151798</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Reck M, Rodriguez-Abreu D, Robinson AG, Hui R, Csoszi T, Fulop A, et al.  Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung Cancer. N Engl J Med. 2016;375(19):1823–1833. doi: 10.1056/NEJMoa1606774.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1056/NEJMoa1606774</ArticleId>
            <ArticleId IdType="pubmed">27718847</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rizvi NA, Hellmann MD, Snyder A, Kvistborg P, Makarov V, Havel JJ, et al.  Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science. 2015;348(6230):124–128. doi: 10.1126/science.aaa1348.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1126/science.aaa1348</ArticleId>
            <ArticleId IdType="pmc">PMC4993154</ArticleId>
            <ArticleId IdType="pubmed">25765070</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Khunger M, Hernandez AV, Pasupuleti V, Rakshit S, Pennell NA, Stevenson J, et al.  Programmed cell death 1 (PD-1) ligand (PD-L1) expression in solid tumors as a predictive biomarker of benefit from PD-1/PD-L1 Axis inhibitors: a systematic review and meta-analysis. JCO Precision Oncology. 2017;1:1–15. doi: 10.1200/PO.16.00030.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1200/PO.16.00030</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Guibert N, Delaunay M, Lusque A, Boubekeur N, Rouquette I, Clermont E, et al.  PD-L1 expression in circulating tumor cells of advanced non-small cell lung cancer patients treated with nivolumab. Lung Cancer. 2018;120:108–112. doi: 10.1016/j.lungcan.2018.04.001.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.lungcan.2018.04.001</ArticleId>
            <ArticleId IdType="pubmed">29748004</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nicolazzo C, Raimondi C, Mancini M, Caponnetto S, Gradilone A, Gandini O, et al.  Monitoring PD-L1 positive circulating tumor cells in non-small cell lung cancer patients treated with the PD-1 inhibitor Nivolumab. Sci Rep. 2016;6:31726. doi: 10.1038/srep31726.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/srep31726</ArticleId>
            <ArticleId IdType="pmc">PMC4995431</ArticleId>
            <ArticleId IdType="pubmed">27553175</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kulasinghe A, Kapeleris J, Kimberley R, Mattarollo SR, Thompson EW, Thiery JP, et al.  The prognostic significance of circulating tumor cells in head and neck and non-small-cell lung cancer. Cancer Med. 2018;7(12):5910–5919. doi: 10.1002/cam4.1832.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/cam4.1832</ArticleId>
            <ArticleId IdType="pmc">PMC6308060</ArticleId>
            <ArticleId IdType="pubmed">30565869</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yue C, Jiang Y, Li P, Wang Y, Xue J, Li N, et al.  Dynamic change of PD-L1 expression on circulating tumor cells in advanced solid tumor patients undergoing PD-1 blockade therapy. Oncoimmunology. 2018;7(7):e1438111. doi: 10.1080/2162402X.2018.1438111.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1080/2162402X.2018.1438111</ArticleId>
            <ArticleId IdType="pmc">PMC5993493</ArticleId>
            <ArticleId IdType="pubmed">29900038</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hoshimoto S, Faries MB, Morton DL, Shingai T, Kuo C, Wang HJ, et al.  Assessment of prognostic circulating tumor cells in a phase III trial of adjuvant immunotherapy after complete resection of stage IV melanoma. Ann Surg. 2012;255(2):357–362. doi: 10.1097/SLA.0b013e3182380f56.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1097/SLA.0b013e3182380f56</ArticleId>
            <ArticleId IdType="pmc">PMC3320770</ArticleId>
            <ArticleId IdType="pubmed">22202581</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Koyanagi K, O'Day SJ, Gonzalez R, Lewis K, Robinson WA, Amatruda TT, et al.  Serial monitoring of circulating melanoma cells during neoadjuvant biochemotherapy for stage III melanoma: outcome prediction in a multicenter trial. J Clin Oncol. 2005;23(31):8057–8064. doi: 10.1200/JCO.2005.02.0958.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1200/JCO.2005.02.0958</ArticleId>
            <ArticleId IdType="pmc">PMC2856446</ArticleId>
            <ArticleId IdType="pubmed">16258104</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hoon DS, Bostick P, Kuo C, Okamoto T, Wang HJ, Elashoff R, et al.  Molecular markers in blood as surrogate prognostic indicators of melanoma recurrence. Cancer Res. 2000;60(8):2253–2257.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">10786692</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Takeuchi H, Morton DL, Kuo C, Turner RR, Elashoff D, Elashoff R, et al.  Prognostic significance of molecular upstaging of paraffin-embedded sentinel lymph nodes in melanoma patients. J Clin Oncol. 2004;22(13):2671–2680. doi: 10.1200/JCO.2004.12.009.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1200/JCO.2004.12.009</ArticleId>
            <ArticleId IdType="pmc">PMC2856457</ArticleId>
            <ArticleId IdType="pubmed">15226334</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nicholl MB, Elashoff D, Takeuchi H, Morton DL, Hoon DS. Molecular upstaging based on paraffin-embedded sentinel lymph nodes: ten-year follow-up confirms prognostic utility in melanoma patients. Ann Surg. 2011;253(1):116–122. doi: 10.1097/SLA.0b013e3181fca894.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1097/SLA.0b013e3181fca894</ArticleId>
            <ArticleId IdType="pmc">PMC3046555</ArticleId>
            <ArticleId IdType="pubmed">21135695</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Koyanagi K, O'Day SJ, Boasberg P, Atkins MB, Wang HJ, Gonzalez R, et al.  Serial monitoring of circulating tumor cells predicts outcome of induction biochemotherapy plus maintenance biotherapy for metastatic melanoma. Clin Cancer Res. 2010;16(8):2402–2408. doi: 10.1158/1078-0432.CCR-10-0037.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/1078-0432.CCR-10-0037</ArticleId>
            <ArticleId IdType="pmc">PMC2855775</ArticleId>
            <ArticleId IdType="pubmed">20371696</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lian S, Xie R, Ye Y, Lu Y, Cheng Y, Xie X, et al.  Dual blockage of both PD-L1 and CD47 enhances immunotherapy against circulating tumor cells. Sci Rep. 2019;9(1):4532. doi: 10.1038/s41598-019-40241-1.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41598-019-40241-1</ArticleId>
            <ArticleId IdType="pmc">PMC6418176</ArticleId>
            <ArticleId IdType="pubmed">30872703</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer. 2012;12(4):252–264. doi: 10.1038/nrc3239.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nrc3239</ArticleId>
            <ArticleId IdType="pmc">PMC4856023</ArticleId>
            <ArticleId IdType="pubmed">22437870</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jaiswal S, Jamieson CH, Pang WW, Park CY, Chao MP, Majeti R, et al.  CD47 is upregulated on circulating hematopoietic stem cells and leukemia cells to avoid phagocytosis. Cell. 2009;138(2):271–285. doi: 10.1016/j.cell.2009.05.046.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.cell.2009.05.046</ArticleId>
            <ArticleId IdType="pmc">PMC2775564</ArticleId>
            <ArticleId IdType="pubmed">19632178</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Murata Y, Saito Y, Kotani T, Matozaki T. CD47-signal regulatory protein α signaling system and its application to cancer immunotherapy. Cancer Sci. 2018;109(8):2349–2357. doi: 10.1111/cas.13663.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/cas.13663</ArticleId>
            <ArticleId IdType="pmc">PMC6113446</ArticleId>
            <ArticleId IdType="pubmed">29873856</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gul N, Babes L, Siegmund K, Korthouwer R, Bogels M, Braster R, et al.  Macrophages eliminate circulating tumor cells after monoclonal antibody therapy. J Clin Invest. 2014;124(2):812–823. doi: 10.1172/JCI66776.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1172/JCI66776</ArticleId>
            <ArticleId IdType="pmc">PMC3904600</ArticleId>
            <ArticleId IdType="pubmed">24430180</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Otten MA, Bij GJ, Van Der VSJ, Falk N, Ravetch JV, et al.  Experimental antibody therapy of liver metastases reveals functional redundancy between fc gammaRI and fc gammaRIV. J Immunol. 2008;181(10):6829–6836. doi: 10.4049/jimmunol.181.10.6829.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.4049/jimmunol.181.10.6829</ArticleId>
            <ArticleId IdType="pubmed">18981101</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bevaart L, Jansen MJ, van Vugt MJ, Verbeek JS, van de Winkel JG, Leusen JH. The high-affinity IgG receptor, FcgammaRI, plays a central role in antibody therapy of experimental melanoma. Cancer Res. 2006;66(3):1261–1264. doi: 10.1158/0008-5472.CAN-05-2856.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/0008-5472.CAN-05-2856</ArticleId>
            <ArticleId IdType="pubmed">16452176</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Van Rooijen N, Sanders A. Liposome mediated depletion of macrophages: mechanism of action, preparation of liposomes and applications. J Immunol Methods. 1994;174(1–2):83–93. doi: 10.1016/0022-1759(94)90012-4.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/0022-1759(94)90012-4</ArticleId>
            <ArticleId IdType="pubmed">8083541</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>van der Bij GJ, Bögels M, Otten MA, Oosterling SJ, Kuppen PJ, Meijer S, et al.  Experimentally induced liver metastases from colorectal cancer can be prevented by mononuclear phagocyte-mediated monoclonal antibody therapy. J Hepatol. 2010;53(4):677–685. doi: 10.1016/j.jhep.2010.04.023.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.jhep.2010.04.023</ArticleId>
            <ArticleId IdType="pubmed">20619916</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mitchell MJ, Wayne E, Rana K, Schaffer CB, King MR. TRAIL-coated leukocytes that kill cancer cells in the circulation. Proc Natl Acad Sci U S A. 2014;111(3):930–935. doi: 10.1073/pnas.1316312111.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1073/pnas.1316312111</ArticleId>
            <ArticleId IdType="pmc">PMC3903223</ArticleId>
            <ArticleId IdType="pubmed">24395803</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Coussens LM, Werb Z. Inflammation and cancer. Nature. 2002;420(6917):860–867. doi: 10.1038/nature01322.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nature01322</ArticleId>
            <ArticleId IdType="pmc">PMC2803035</ArticleId>
            <ArticleId IdType="pubmed">12490959</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Braedon MD, Jonathan S, Betty G, Lucia F, Pnina B, Ferri LE, et al.  Systemic inflammation increases cancer cell adhesion to hepatic sinusoids by neutrophil mediated mechanisms. Int J Cancer. 2010;125(6):1298–1305.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19431213</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>van Ginhoven TM, van den Berg JW, Dik WA, Ijzermans JN, de Bruin RW. Preoperative dietary restriction reduces hepatic tumor load by reduced E-selectin-mediated adhesion in mice. J Surg Oncol. 2010;102(4):348–353. doi: 10.1002/jso.21649.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/jso.21649</ArticleId>
            <ArticleId IdType="pubmed">20672315</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gassmann P, Kang ML, Mees ST, Haier J. In vivo tumor cell adhesion in the pulmonary microvasculature is exclusively mediated by tumor cell - endothelial cell interaction. BMC Cancer. 2010;10:177. doi: 10.1186/1471-2407-10-177.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/1471-2407-10-177</ArticleId>
            <ArticleId IdType="pmc">PMC2874534</ArticleId>
            <ArticleId IdType="pubmed">20433713</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Köhler S, Ullrich S, Richter U, Schumacher U. E−/P-selectins and colon carcinoma metastasis: first in vivo evidence for their crucial role in a clinically relevant model of spontaneous metastasis formation in the lung. Br J Cancer. 2010;102(3):602–609. doi: 10.1038/sj.bjc.6605492.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/sj.bjc.6605492</ArticleId>
            <ArticleId IdType="pmc">PMC2822933</ArticleId>
            <ArticleId IdType="pubmed">20010946</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rahn JJ, Chow JW, Horne GJ, Mah BK, Emerman JT, Hoffman P, et al.  MUC1 mediates Transendothelial migration in vitro by ligating endothelial cell ICAM-1. Clin Exp Metastasis. 2005;22(6):475–483. doi: 10.1007/s10585-005-3098-x.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s10585-005-3098-x</ArticleId>
            <ArticleId IdType="pubmed">16320110</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Läubli H, Borsig L. Selectins promote tumor metastasis. Semin Cancer Biol. 2010;20(3):169–177. doi: 10.1016/j.semcancer.2010.04.005.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.semcancer.2010.04.005</ArticleId>
            <ArticleId IdType="pubmed">20452433</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yu M, Stott S, Toner M, Maheswaran S, Haber DA. Circulating tumor cells: approaches to isolation and characterization. J Cell Biol. 2011;192(3):373–382. doi: 10.1083/jcb.201010021.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1083/jcb.201010021</ArticleId>
            <ArticleId IdType="pmc">PMC3101098</ArticleId>
            <ArticleId IdType="pubmed">21300848</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Firrell JC, Lipowsky HH. Leukocyte margination and deformation in mesenteric venules of rat. Am J Phys. 1989;256(6 Pt 2):H1667–H1674.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">2735435</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang C, Sun W, Ye Y, Hu Q, Bomba HN, Gu Z. In situ activation of platelets with checkpoint inhibitors for post-surgical cancer immunotherapy. Nat Biomed Eng. 2017;1:0011. doi: 10.1038/s41551-016-0011.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41551-016-0011</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gay LJ, Felding-Habermann B. Contribution of platelets to tumour metastasis. Nat Rev Cancer. 2011;11(2):123–134. doi: 10.1038/nrc3004.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nrc3004</ArticleId>
            <ArticleId IdType="pmc">PMC6894505</ArticleId>
            <ArticleId IdType="pubmed">21258396</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gong L, Cai Y, Zhou X, Yang H. Activated platelets interact with lung cancer cells through P-selectin glycoprotein ligand-1. Pathol Oncol Res. 2012;18(4):989–996. doi: 10.1007/s12253-012-9531-y.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s12253-012-9531-y</ArticleId>
            <ArticleId IdType="pubmed">22535539</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kanikarla-Marie P, Lam M, Menter DG, Kopetz S. Platelets, circulating tumor cells, and the circulome. Cancer Metastasis Rev. 2017;36(2):235–248. doi: 10.1007/s10555-017-9681-1.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s10555-017-9681-1</ArticleId>
            <ArticleId IdType="pubmed">28667367</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mohme M, Riethdorf S, Pantel K. Circulating and disseminated tumour cells - mechanisms of immune surveillance and escape. Nat Rev Clin Oncol. 2017;14(3):155–167. doi: 10.1038/nrclinonc.2016.144.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nrclinonc.2016.144</ArticleId>
            <ArticleId IdType="pubmed">27644321</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Freeman GJ, Long AJ, Iwai Y, Bourque K, Chernova T, Nishimura H, et al.  Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. J Exp Med. 2000;192(7):1027–1034. doi: 10.1084/jem.192.7.1027.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1084/jem.192.7.1027</ArticleId>
            <ArticleId IdType="pmc">PMC2193311</ArticleId>
            <ArticleId IdType="pubmed">11015443</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sun C, Mezzadra R, Schumacher TN. Regulation and function of the PD-L1 checkpoint. Immunity. 2018;48(3):434–452. doi: 10.1016/j.immuni.2018.03.014.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.immuni.2018.03.014</ArticleId>
            <ArticleId IdType="pmc">PMC7116507</ArticleId>
            <ArticleId IdType="pubmed">29562194</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chen Z, Hu Q, Gu Z. Leveraging engineering of cells for drug delivery. Acc Chem Res. 2018;51(3):668–677. doi: 10.1021/acs.accounts.7b00526.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1021/acs.accounts.7b00526</ArticleId>
            <ArticleId IdType="pubmed">29446615</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ruggeri ZM, Mendolicchio GL. Adhesion mechanisms in platelet function. Circ Res. 2007;100(12):1673–1685. doi: 10.1161/01.RES.0000267878.97021.ab.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1161/01.RES.0000267878.97021.ab</ArticleId>
            <ArticleId IdType="pubmed">17585075</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mezouar S, Mege D, Darbousset R, Farge D, Debourdeau P, Dignat-George F, et al.  Involvement of platelet-derived microparticles in tumor progression and thrombosis. Semin Oncol. 2014;41(3):346–358. doi: 10.1053/j.seminoncol.2014.04.010.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1053/j.seminoncol.2014.04.010</ArticleId>
            <ArticleId IdType="pubmed">25023350</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mishra DK, Rocha HJ, Miller R, Kim MP. Immune cells inhibit the tumor metastasis in the 4D cellular lung model by reducing the number of live circulating tumor cells. Sci Rep. 2018;8(1):16569. doi: 10.1038/s41598-018-34983-7.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41598-018-34983-7</ArticleId>
            <ArticleId IdType="pmc">PMC6224572</ArticleId>
            <ArticleId IdType="pubmed">30410108</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kokolus KM, Zhang Y, Sivik JM, Schmeck C, Zhu J, Repasky EA, et al.  Beta blocker use correlates with better overall survival in metastatic melanoma patients and improves the efficacy of immunotherapies in mice. Oncoimmunology. 2017;7(3):e1405205. doi: 10.1080/2162402X.2017.1405205.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1080/2162402X.2017.1405205</ArticleId>
            <ArticleId IdType="pmc">PMC5790362</ArticleId>
            <ArticleId IdType="pubmed">29399407</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nedosekin DA, Sarimollaoglu M, Ye JH, Galanzha EI, Zharov VP. In vivo ultra-fast photoacoustic flow cytometry of circulating human melanoma cells using near-infrared high-pulse rate lasers. Cytometry A. 2011;79(10):825–833. doi: 10.1002/cyto.a.21102.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/cyto.a.21102</ArticleId>
            <ArticleId IdType="pmc">PMC3208323</ArticleId>
            <ArticleId IdType="pubmed">21786417</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tartour E, Pere H, Maillere B, Terme M, Merillon N, Taieb J, et al.  Angiogenesis and immunity: a bidirectional link potentially relevant for the monitoring of antiangiogenic therapy and the development of novel therapeutic combination with immunotherapy. Cancer Metastasis Rev. 2011;30(1):83–95. doi: 10.1007/s10555-011-9281-4.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s10555-011-9281-4</ArticleId>
            <ArticleId IdType="pubmed">21249423</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Toh B, Wang X, Keeble J, Sim WJ, Khoo K, Wong WC, et al.  Mesenchymal transition and dissemination of cancer cells is driven by myeloid-derived suppressor cells infiltrating the primary tumor. PLoS Biol. 2011;9(9):e1001162. doi: 10.1371/journal.pbio.1001162.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1371/journal.pbio.1001162</ArticleId>
            <ArticleId IdType="pmc">PMC3181226</ArticleId>
            <ArticleId IdType="pubmed">21980263</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Oh K, Lee OY, Shon SY, Nam O, Ryu PM, Seo MW, et al.  A mutual activation loop between breast cancer cells and myeloid-derived suppressor cells facilitates spontaneous metastasis through IL-6 trans-signaling in a murine model. Breast Cancer Res. 2013;15(5):R79. doi: 10.1186/bcr3473.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/bcr3473</ArticleId>
            <ArticleId IdType="pmc">PMC3979084</ArticleId>
            <ArticleId IdType="pubmed">24021059</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lambert AW, Pattabiraman DR, Weinberg RA. Emerging biological principles of metastasis. Cell. 2017;168(4):670–691. doi: 10.1016/j.cell.2016.11.037.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.cell.2016.11.037</ArticleId>
            <ArticleId IdType="pmc">PMC5308465</ArticleId>
            <ArticleId IdType="pubmed">28187288</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang R, Zhang J, Chen S, Lu M, Luo X, Yao S, et al.  Tumor-associated macrophages provide a suitable microenvironment for non-small lung cancer invasion and progression. Lung Cancer. 2011;74(2):188–196. doi: 10.1016/j.lungcan.2011.04.009.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.lungcan.2011.04.009</ArticleId>
            <ArticleId IdType="pubmed">21601305</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Noy R, Pollard JW. Tumor-associated macrophages: from mechanisms to therapy. Immunity. 2014;41(1):49–61. doi: 10.1016/j.immuni.2014.06.010.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.immuni.2014.06.010</ArticleId>
            <ArticleId IdType="pmc">PMC4137410</ArticleId>
            <ArticleId IdType="pubmed">25035953</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhang N, Zhang WJ, Cai HQ, Liu HL, Peng L, Li CH, et al.  Platelet adhesion and fusion to endothelial cell facilitate the metastasis of tumor cell in hypoxia-reoxygenation condition. Clin Exp Metastasis. 2011;28(1):1–12. doi: 10.1007/s10585-010-9353-9.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s10585-010-9353-9</ArticleId>
            <ArticleId IdType="pubmed">21061145</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Spicer JD, McDonald B, Cools-Lartigue JJ, Chow SC, Giannias B, Kubes P, et al.  Neutrophils promote liver metastasis via mac-1-mediated interactions with circulating tumor cells. Cancer Res. 2012;72(16):3919–3927. doi: 10.1158/0008-5472.CAN-11-2393.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/0008-5472.CAN-11-2393</ArticleId>
            <ArticleId IdType="pubmed">22751466</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cools-Lartigue Jonathan, Spicer Jonathan, McDonald Braedon, Gowing Stephen, Chow Simon, Giannias Betty, Bourdeau France, Kubes Paul, Ferri Lorenzo. Neutrophil extracellular traps sequester circulating tumor cells and promote metastasis. Journal of Clinical Investigation. 2013;123(8):3446–3458. doi: 10.1172/JCI67484.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1172/JCI67484</ArticleId>
            <ArticleId IdType="pmc">PMC3726160</ArticleId>
            <ArticleId IdType="pubmed">23863628</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jiang H, Gebhardt C, Umansky L, Beckhove P, Schulze TJ, Utikal J, et al.  Elevated chronic inflammatory factors and myeloid-derived suppressor cells indicate poor prognosis in advanced melanoma patients. Int J Cancer. 2015;136(10):2352–2360. doi: 10.1002/ijc.29297.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/ijc.29297</ArticleId>
            <ArticleId IdType="pubmed">25353097</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mego M, Gao H, Cohen EN, Anfossi S, Giordano A, Tin S, et al.  Circulating tumor cells (CTCs) are associated with abnormalities in peripheral blood dendritic cells in patients with inflammatory breast cancer. Oncotarget. 2017;8(22):35656–35668. doi: 10.18632/oncotarget.10290.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.18632/oncotarget.10290</ArticleId>
            <ArticleId IdType="pmc">PMC5482606</ArticleId>
            <ArticleId IdType="pubmed">27374101</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Placke T, Orgel M, Schaller M, Jung G, Rammensee HG, Kopp HG, et al.  Platelet-derived MHC class I confers a pseudonormal phenotype to cancer cells that subverts the antitumor reactivity of natural killer immune cells. Cancer Res. 2012;72(2):440–448. doi: 10.1158/0008-5472.CAN-11-1872.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/0008-5472.CAN-11-1872</ArticleId>
            <ArticleId IdType="pubmed">22127925</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wu MS, Li CH, Ruppert JG, Chang CC. Cytokeratin 8-MHC class I interactions: a potential novel immune escape phenotype by a lymph node metastatic carcinoma cell line. Biochem Biophys Res Commun. 2013;441(3):618–623. doi: 10.1016/j.bbrc.2013.10.105.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.bbrc.2013.10.105</ArticleId>
            <ArticleId IdType="pubmed">24183726</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Moll R, Franke WW, Schiller DL, Geiger B, Krepler R. The catalog of human cytokeratins: patterns of expression in normal epithelia, tumors and cultured cells. Cell. 1982;31(1):11–24. doi: 10.1016/0092-8674(82)90400-7.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/0092-8674(82)90400-7</ArticleId>
            <ArticleId IdType="pubmed">6186379</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gordon N, Kleinerman ES. The role of Fas/FasL in the metastatic potential of osteosarcoma and targeting this pathway for the treatment of osteosarcoma lung metastases. Cancer Treat Res. 2009;152:497–508. doi: 10.1007/978-1-4419-0284-9_29.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/978-1-4419-0284-9_29</ArticleId>
            <ArticleId IdType="pubmed">20213411</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Strauss L, Bergmann C, Whiteside TL. Human circulating CD4+CD25highFoxp3+ regulatory T cells kill autologous CD8+ but not CD4+ responder cells by Fas-mediated apoptosis. J Immunol. 2009;182(3):1469–1480. doi: 10.4049/jimmunol.182.3.1469.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.4049/jimmunol.182.3.1469</ArticleId>
            <ArticleId IdType="pmc">PMC3721355</ArticleId>
            <ArticleId IdType="pubmed">19155494</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hallermalm K, De Geer A, Kiessling R, Levitsky V, Levitskaya J. Autocrine secretion of Fas ligand shields tumor cells from Fas-mediated killing by cytotoxic lymphocytes. Cancer Res. 2004;64(18):6775–6782. doi: 10.1158/0008-5472.CAN-04-0508.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/0008-5472.CAN-04-0508</ArticleId>
            <ArticleId IdType="pubmed">15374996</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ugurel S, Rappl G, Tilgen W, Reinhold U. Increased soluble CD95 (sFas/CD95) serum level correlates with poor prognosis in melanoma patients. Clin Cancer Res. 2001;7(5):1282–1286.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11350895</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cheng J, Zhou T, Liu C, Shapiro JP, Brauer MJ, Kiefer MC, et al.  Protection from Fas-mediated apoptosis by a soluble form of the Fas molecule. Science. 1994;263(5154):1759–1762. doi: 10.1126/science.7510905.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1126/science.7510905</ArticleId>
            <ArticleId IdType="pubmed">7510905</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zou W, Chen L. Inhibitory B7-family molecules in the tumour microenvironment. Nat Rev Immunol. 2008;8(6):467–477. doi: 10.1038/nri2326.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nri2326</ArticleId>
            <ArticleId IdType="pubmed">18500231</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>He X, Dong DD, Yie SM, Yang H, Cao M, Ye SR, et al.  HLA-G expression in human breast cancer: implications for diagnosis and prognosis, and effect on allocytotoxic lymphocyte response after hormone treatment in vitro. Ann Surg Oncol. 2010;17(5):1459–1469. doi: 10.1245/s10434-009-0891-9.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1245/s10434-009-0891-9</ArticleId>
            <ArticleId IdType="pubmed">20052552</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>de Kruijf EM, Sajet A, van Nes JG, Natanov R, Putter H, Smit VT, et al.  HLA-E and HLA-G expression in classical HLA class I-negative tumors is of prognostic value for clinical outcome of early breast cancer patients. J Immunol. 2010;185(12):7452–7459. doi: 10.4049/jimmunol.1002629.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.4049/jimmunol.1002629</ArticleId>
            <ArticleId IdType="pubmed">21057081</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Guo ZY, Lv YG, Wang L, Shi SJ, Yang F, Zheng GX, et al.  Predictive value of HLA-G and HLA-E in the prognosis of colorectal cancer patients. Cell Immunol. 2015;293(1):10–16. doi: 10.1016/j.cellimm.2014.10.003.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.cellimm.2014.10.003</ArticleId>
            <ArticleId IdType="pubmed">25461612</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cai MY, Xu YF, Qiu SJ, Ju MJ, Gao Q, Li YW, et al.  Human leukocyte antigen-G protein expression is an unfavorable prognostic predictor of hepatocellular carcinoma following curative resection. Clin Cancer Res. 2009;15(14):4686–4693. doi: 10.1158/1078-0432.CCR-09-0463.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/1078-0432.CCR-09-0463</ArticleId>
            <ArticleId IdType="pubmed">19584149</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Contini P, Ghio M, Poggi A, Filaci G, Indiveri F, Ferrone S, et al.  Soluble HLA-A,-B,-C and -G molecules induce apoptosis in T and NK CD8+ cells and inhibit cytotoxic T cell activity through CD8 ligation. Eur J Immunol. 2003;33(1):125–134. doi: 10.1002/immu.200390015.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/immu.200390015</ArticleId>
            <ArticleId IdType="pubmed">12594841</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lopez-Soto A, Gonzalez S, Smyth MJ, Galluzzi L. Control of metastasis by NK cells. Cancer Cell. 2017;32(2):135–154. doi: 10.1016/j.ccell.2017.06.009.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.ccell.2017.06.009</ArticleId>
            <ArticleId IdType="pubmed">28810142</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang B, Wang Q, Wang Z, Jiang J, Yu SC, Ping YF, et al.  Metastatic consequences of immune escape from NK cell cytotoxicity by human breast cancer stem cells. Cancer Res. 2014;74(20):5746–5757. doi: 10.1158/0008-5472.CAN-13-2563.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/0008-5472.CAN-13-2563</ArticleId>
            <ArticleId IdType="pubmed">25164008</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Barsoum IB, Hamilton TK, Li X, Cotechini T, Miles EA, Siemens DR, et al.  Hypoxia induces escape from innate immunity in cancer cells via increased expression of ADAM10: role of nitric oxide. Cancer Res. 2011;71(24):7433–7441. doi: 10.1158/0008-5472.CAN-11-2104.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/0008-5472.CAN-11-2104</ArticleId>
            <ArticleId IdType="pubmed">22006996</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Crane CA, Austgen K, Haberthur K, Hofmann C, Moyes KW, Avanesyan L, et al.  Immune evasion mediated by tumor-derived lactate dehydrogenase induction of NKG2D ligands on myeloid cells in glioblastoma patients. Proc Natl Acad Sci U S A. 2014;111(35):12823–12828. doi: 10.1073/pnas.1413933111.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1073/pnas.1413933111</ArticleId>
            <ArticleId IdType="pmc">PMC4156766</ArticleId>
            <ArticleId IdType="pubmed">25136121</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Deng W, Gowen BG, Zhang L, Wang L, Lau S, Iannello A, et al.  Antitumor immunity. A shed NKG2D ligand that promotes natural killer cell activation and tumor rejection. Science. 2015;348(6230):136–139. doi: 10.1126/science.1258867.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1126/science.1258867</ArticleId>
            <ArticleId IdType="pmc">PMC4856222</ArticleId>
            <ArticleId IdType="pubmed">25745066</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nieswandt B, Hafner M, Echtenacher B, Mannel DN. Lysis of tumor cells by natural killer cells in mice is impeded by platelets. Cancer Res. 1999;59(6):1295–1300.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">10096562</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Im JH, Fu W, Wang H, Bhatia SK, Hammer DA, Kowalska MA, et al.  Coagulation facilitates tumor cell spreading in the pulmonary vasculature during early metastatic colony formation. Cancer Res. 2004;64(23):8613–8619. doi: 10.1158/0008-5472.CAN-04-2078.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/0008-5472.CAN-04-2078</ArticleId>
            <ArticleId IdType="pubmed">15574768</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Steinert G, Scholch S, Niemietz T, Iwata N, Garcia SA, Behrens B, et al.  Immune escape and survival mechanisms in circulating tumor cells of colorectal cancer. Cancer Res. 2014;74(6):1694–1704. doi: 10.1158/0008-5472.CAN-13-1885.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/0008-5472.CAN-13-1885</ArticleId>
            <ArticleId IdType="pubmed">24599131</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chao MP, Tang C, Pachynski RK, Chin R, Majeti R, Weissman IL. Extranodal dissemination of non-Hodgkin lymphoma requires CD47 and is inhibited by anti-CD47 antibody therapy. Blood. 2011;118(18):4890–4901. doi: 10.1182/blood-2011-02-338020.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1182/blood-2011-02-338020</ArticleId>
            <ArticleId IdType="pmc">PMC3208297</ArticleId>
            <ArticleId IdType="pubmed">21828138</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Alfaro C, Suarez N, Gonzalez A, Solano S, Erro L, Dubrot J, et al.  Influence of bevacizumab, sunitinib and sorafenib as single agents or in combination on the inhibitory effects of VEGF on human dendritic cell differentiation from monocytes. Br J Cancer. 2009;100(7):1111–1119. doi: 10.1038/sj.bjc.6604965.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/sj.bjc.6604965</ArticleId>
            <ArticleId IdType="pmc">PMC2670006</ArticleId>
            <ArticleId IdType="pubmed">19277038</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Roland CL, Lynn KD, Toombs JE, Dineen SP, Udugamasooriya DG, Brekken RA. Cytokine levels correlate with immune cell infiltration after anti-VEGF therapy in preclinical mouse models of breast cancer. PLoS One. 2009;4(11):e7669. doi: 10.1371/journal.pone.0007669.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1371/journal.pone.0007669</ArticleId>
            <ArticleId IdType="pmc">PMC2766251</ArticleId>
            <ArticleId IdType="pubmed">19888452</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gigante M, Gesualdo L, Ranieri E. TGF-beta: a master switch in tumor immunity. Curr Pharm Des. 2012;18(27):4126–4134. doi: 10.2174/138161212802430378.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.2174/138161212802430378</ArticleId>
            <ArticleId IdType="pubmed">22630082</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
